- Dyax (DYAX) says the first subject has been dosed in a Phase 1 trial for subQ DX-2930, the company's fully human monoclonal antibody inhibitor of plasma kallikrein. (PR)
- SubQ DX-2930 is being developed for the prevention of HAE attacks.
- Other notable HAE drugs: BCRX's BCX-4161 and VPHM's Cinryze
Next headline on your portfolio: